| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/04/2009 | CA2706633A1 Novel cancer-associated antibody and antigen |
| 06/04/2009 | CA2706620A1 Conjugated beta-1,3-linked glucans |
| 06/04/2009 | CA2706517A1 Nanoemulsions |
| 06/04/2009 | CA2706448A1 Solvent systems for pour-on formulations for combating parasites |
| 06/04/2009 | CA2706379A1 A method for producing adapalene gels |
| 06/04/2009 | CA2704836A1 Oligomer-tricyclic conjugates |
| 06/04/2009 | CA2704826A1 Method for producing granulated preparation |
| 06/03/2009 | EP2065705A1 Stabilization of conjugates comprising a thiourea linker |
| 06/03/2009 | EP2065075A1 Water-in-oil emulsion composition and cosmetic emulsion comprising the same |
| 06/03/2009 | EP2065057A2 Chelating conjugates having a substituted aromatic moiety and derivatives thereof |
| 06/03/2009 | EP2065056A1 Hydrophilic matrix having poorly water-soluble compound sealed therein, and method for producing the same |
| 06/03/2009 | EP2065055A1 Holt-melt extrudable pharmaceutical formulation |
| 06/03/2009 | EP2065052A2 Anti-IgE vaccines |
| 06/03/2009 | EP2065047A1 Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| 06/03/2009 | EP2065043A1 Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent |
| 06/03/2009 | EP2065042A2 Antiparasitic composition containing an organic amine salt of closantel |
| 06/03/2009 | EP2065033A1 Microemulsions of cannabinoid receptor binding compounds |
| 06/03/2009 | EP2065032A1 A method for producing adapalene gels |
| 06/03/2009 | EP2064252A2 Process for the preparation of sevelamer hydrochloride and formulation thereof |
| 06/03/2009 | EP2063914A1 Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation |
| 06/03/2009 | EP2063913A2 Antigenic protein conjugates and process for preparing same |
| 06/03/2009 | EP2063881A2 A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
| 06/03/2009 | EP2063879A2 Compositions of chk1 inhibitors and cyclodextrin |
| 06/03/2009 | EP2063868A1 Pharmaceutical compositions containing rosuvastatin calcium |
| 06/03/2009 | EP2063864A2 Edible water-soluble film containing a foam reducing flavoring agent |
| 06/03/2009 | EP2063863A2 Drug electrotransport with hydration measurement of hydratable reservoir |
| 06/03/2009 | EP1863469A4 A topical analgesic composition |
| 06/03/2009 | EP1732535B1 Injectable composition for the treatment of cancers |
| 06/03/2009 | EP1480618B1 Sustained release drug formulations containing a carrier peptide |
| 06/03/2009 | EP1379197A4 Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
| 06/03/2009 | EP1366759B1 Tablets quickly disintegrating in oral cavity |
| 06/03/2009 | EP1187636B1 Injectable hyaluronate-sulfated polysaccharide conjugates |
| 06/03/2009 | EP1035836B1 Composition comprising an enzym, a stabilizer for the enzym and a process for ameliorating the stability of the enzyme, to prevent its degradation, to protect it and/or to immobilise it |
| 06/03/2009 | CN101448525A Polyethylene glycol-interferon alpha conjugate |
| 06/03/2009 | CN101445494A Conjugated psychotropic drugs and uses thereof |
| 06/03/2009 | CN101444627A Chitosan/rectories nano-composite for medical carriers and method for preparing same |
| 06/03/2009 | CN101444470A Use of oligosaccharides to stimulate beta-endorphin production |
| 06/03/2009 | CN100494256C Polymer composite with internally distributed deposition matter |
| 06/03/2009 | CN100493618C Series non-virus vector, and medicinal composition containing same |
| 06/03/2009 | CN100493615C Monomodified PEGylated insulin and its preparation method |
| 06/03/2009 | CN100493614C Anticancer medicine-chitosan complex for forming self-aggregates and preparation method thereof |
| 06/03/2009 | CN100493613C A method to improve surface properties of pharmaceutical tablets |
| 06/03/2009 | CN100493612C Wound bandage and plaster |
| 06/03/2009 | CN100493611C Liposome and its preparation process |
| 06/03/2009 | CN100493610C Composition of sodium fusidafe for injection and preparing method thereof |
| 06/02/2009 | US7541436 covalently attached to a nonpeptide polyoxyethylene glycol moiety; nucleic acids encoding the polypeptides; reducing the number of copies of a virus in infected cells; drugs/polymer conjugates/ as viricides treating Hepatitis-C virus |
| 06/02/2009 | US7541350 Formulation containing anti-inflammatory androstane derivative |
| 06/02/2009 | US7541334 Hybrid peptides modulate the immune response |
| 06/02/2009 | US7541330 Conjugates with reduced adverse systemic effects |
| 06/02/2009 | US7541329 Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease |
| 06/02/2009 | US7541328 Coupling proteins to a modified polysaccharide |
| 06/02/2009 | US7541163 Expression vector comprising nucleotide sequences coding multifunctional protein with viricidal activity |
| 06/02/2009 | US7541047 Method for production of shaped body for treating wounds in milk producing animals |
| 06/02/2009 | US7541044 stimulating antitumor immune responses; tissue-targeted therapy; first tumour antigen is used to treat secondary tumor; biodrug for cancer immunotherapy with cyclophosphamide |
| 06/02/2009 | US7541042 Topical compositions containing Bacillus coagulans extracellular products and uses thereof |
| 06/02/2009 | US7541041 Vaccine against dental caries based on virulence-associated immunomodulatory extracellular proteins produced by the cariogenic bacteria Streptococcus sobrinus and Streptococcus mutans |
| 06/02/2009 | US7541040 Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
| 06/02/2009 | US7541036 Human immunodeficiency virus type 1 (HIV-1) matrix (MA or p17) polypeptide capable of inducing anti-p17 antibodies that neutralize the proinflammatory activities of the MA protein |
| 06/02/2009 | US7541034 Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
| 06/02/2009 | US7541020 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| 06/02/2009 | US7540382 Stabilized liquid protein formulations in pharmaceutical containers |
| 06/02/2009 | CA2396223C Instant granules and process for their formulation |
| 06/02/2009 | CA2387143C Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin |
| 06/02/2009 | CA2386890C Artificial tear replacement solution |
| 06/02/2009 | CA2371728C High dose radionuclide complexes for bone marrow suppression |
| 06/02/2009 | CA2366793C Propofol formulation with enhanced microbial characteristics |
| 06/02/2009 | CA2356774C Method and device for preparing a medical fluid |
| 06/02/2009 | CA2349633C A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
| 06/02/2009 | CA2340416C Co-lyophilized complex of a nucleic acid vector and a formulating agent |
| 06/02/2009 | CA2326137C Method for stabilizing pharmaceutical compositions by special use of an antioxidant |
| 06/02/2009 | CA2304950C Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection |
| 06/02/2009 | CA2249351C Novel method of diagnosing and treating gliomas |
| 06/02/2009 | CA2247388C Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components |
| 06/02/2009 | CA2244089C Dermal penetration enhancers and drug delivery systems involving same |
| 06/02/2009 | CA2226548C Lyophilized hepatocyte growth factor preparations |
| 06/02/2009 | CA2190867C Methods for reduced renal uptake of antibody fragments |
| 06/02/2009 | CA2158475C Composition and method for reducing toxicity of biologically-active factors |
| 05/30/2009 | CA2612999A1 Modified release composition of at least one form of venlafaxine |
| 05/28/2009 | WO2009067663A1 Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds |
| 05/28/2009 | WO2009067536A2 Formulation for decreasing tobacco, alcohol, drug or food consumption |
| 05/28/2009 | WO2009067535A1 Topical composition for treating pain |
| 05/28/2009 | WO2009067175A2 Oligomer-dantrolene conjugates and related compounds |
| 05/28/2009 | WO2009066775A1 Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same |
| 05/28/2009 | WO2009066773A1 Orally disintegrating tablet |
| 05/28/2009 | WO2009066763A1 Preparation for application to body surface and preparation holding sheet for application to body surface |
| 05/28/2009 | WO2009066644A1 Spherical particle and method for producing the same |
| 05/28/2009 | WO2009066468A1 Particulate medical material and use thereof |
| 05/28/2009 | WO2009066457A1 External preparation composition comprising fatty acid-based ionic liquid as active ingredient |
| 05/28/2009 | WO2009066262A1 Preparations, methods and kits useful for treatment of cough |
| 05/28/2009 | WO2009065947A2 Pharmaceutical composition containing a zeolite/algae or zeolite/emulsion combination for the treatment of aids |
| 05/28/2009 | WO2009065946A2 Pharmaceutical kit consisting of an oil-in-water emulsion and a solid composition |
| 05/28/2009 | WO2009065918A1 Stabilisation of liquid-formulated factor vii(a) polypeptides by aldehyde-containing compounds |
| 05/28/2009 | WO2009065565A1 Rinse solution |
| 05/28/2009 | WO2009065561A2 System for delivery into a xcr1 positive cell and uses thereof |
| 05/28/2009 | WO2009065514A1 Stabilisation of oily suspensions containing hydrophobic silicic acids |
| 05/28/2009 | WO2009048959A8 Rapid acting injectable insulin compositions |
| 05/28/2009 | WO2009048280A3 Long acting hyaluronic acid - peptide conjugate |
| 05/28/2009 | WO2009036933A9 Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles |
| 05/28/2009 | WO2009036204A3 Phase ii detoxification and antioxidant activity |
| 05/28/2009 | WO2008130382A3 Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |